Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients
Annual EBITDA margin expands by 170 basis points
The decision to withdraw the BLA is based on topline overall survival (OS) results from the confirmatory HERTHENA-Lung02 Phase 3 trial where OS did not meet statistical significance
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
IICP is a registered charitable society working in the disability sector since 1974
She has held senior positions at Coca-Cola in China and PepsiCo in India
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
This significant milestone enhances our global regulatory standing
Subscribe To Our Newsletter & Stay Updated
